BiotechTube

SAL056 (56.5μg) + Alendronate

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Women With Osteoporosis

Conditions

Postmenopausal Women With Osteoporosis

Trial Timeline

Dec 3, 2021 → May 20, 2024

NCT ID
NCT07028320

About SAL056 (56.5μg) + Alendronate

SAL056 (56.5μg) + Alendronate is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Postmenopausal Women With Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT07028320. Target conditions include Postmenopausal Women With Osteoporosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07028320Phase 3Completed

Competing Products

20 competing products in Postmenopausal Women With Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
LetrozoleChugai PharmaceuticalPhase 2
52
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
LetrozoleChugai PharmaceuticalPhase 2
52
LetrozoleChugai PharmaceuticalPhase 2
52
menatetranone + alfacalcidolEisaiPhase 3
77
teriparatide + raloxifene + placeboEli LillyPhase 3
77
Teriparatide + Strontium ranelateEli LillyApproved
85
teriparatideEli LillyApproved
85
LY333334 + PlaceboEli LillyPhase 1
33
Teriparatide + RaloxifeneEli LillyApproved
85
teriparatide + aldrenodate + raloxifeneEli LillyApproved
85
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
BlosozumabEli LillyPhase 1
33
Arzoxifene + RaloxifeneEli LillyPhase 3
77
teriparatide + raloxifene HCl + placeboEli LillyApproved
85

Other Products from Shenzhen Salubris Pharmaceuticals

Allisartan Isoproxil Tablets 240mg or placebo + Allisartan Isoproxil Tablets 480mg or placebo + Allisartan Isoproxil Tablets 720mg or placeboApproved
84
Enarodustat 2mg + Enarodustat 3mg + Enarodustat 4mgApproved
84
ClopidogrelApproved
84
SAL-0951 + PlaceboPhase 3
76
SAL067 + Alogliptin + PlaceboPhase 3
76